7 documents

Read All
22:30 , Feb 2, 2018 |  BioCentury  |  Product Development

AA Viral meme

Gene therapy pioneer James Wilson’s revelation of two new types of toxicity in animals receiving high systemic doses of adeno-associated viral vectors is unlikely to herald a major disruption of the AAV space, though it...
Read More
22:46 , Sep 20, 2017 |  BC Extra  |  Company News

Synpromics, Solid targeting DMD with transcription promoters

Synpromics Ltd. (Edinburgh, U.K.) will provide Solid Biosciences LLC (Cambridge, Mass.) access to muscle-selective synthetic DNA transcription promoter candidates based on Synpromics' PromPT platform which will be used to develop therapies for Duchenne muscular dystrophy....
Read More
22:33 , Jun 21, 2017 |  BC Extra  |  Company News

Sarepta gets option for Genethon's DMD gene therapy

Sarepta Therapeutics Inc. (NASDAQ:SRPT) said it gained an option to obtain exclusive U.S. rights from non-profit organization Genethon (Evry, France) to a gene therapy to treat Duchenne muscular dystrophy. The collaboration covers a Genethon preclinical...
Read More
07:00 , Aug 8, 2016 |  BC Week In Review  |  Company News

Bamboo, Pfizer deal

Pfizer acquired the 78% of Bamboo it did not already own for $150 million up front and up to $495 million in development, regulatory and commercialization milestones. In 1Q16, the pharma obtained a 22% stake...
Read More
07:00 , Aug 1, 2016 |  BC Extra  |  Company News

Pfizer acquires gene therapy company Bamboo

Pfizer Inc. (NYSE:PFE) acquired the 78% of Bamboo Therapeutics Inc. (Chapel Hill, N.C.) it did not already own for $150 million up front and $495 million in milestones. In 1Q16, the pharma obtained a 22%...
Read More
07:00 , Jul 18, 2016 |  BioCentury  |  Emerging Company Profile

Harnessing AAV tropisms

Bamboo Therapeutics Inc. is developing adeno-associated viral vector-based gene therapies that preferentially target tissues affected by CNS and neuromuscular disorders. By homing in on specific tissues, Bamboo's gene therapies could minimize off-target toxicities and reduce...
Read More
02:58 , Feb 13, 2016 |  BC Extra  |  Financial News

Gene therapy play Bamboo raises $49.5M

Bamboo Therapeutics Inc. (Chapel Hill, N.C) raised $49.5 million in a series A round. Bamboo Co-Founder and CEO Sheila Mikhail declined to name any of the investors except CureDuchenne Ventures LLC, whose investment was announced...
Read More